S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Vatican singles out bishops in urging reflective not reactive social media use
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Vatican singles out bishops in urging reflective not reactive social media use
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Vatican singles out bishops in urging reflective not reactive social media use
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Vatican singles out bishops in urging reflective not reactive social media use
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
NASDAQ:LMDX

LumiraDx (LMDX) Stock Forecast, Price & News

$0.48
-0.02 (-3.25%)
(As of 05/26/2023 08:47 PM ET)
Compare
Today's Range
$0.45
$0.51
50-Day Range
$0.47
$0.86
52-Week Range
$0.45
$4.50
Volume
150,200 shs
Average Volume
172,979 shs
Market Capitalization
$152.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.14

LumiraDx MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
346.2% Upside
$2.14 Price Target
Short Interest
Bearish
12.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.51) to ($0.39) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

746th out of 1,010 stocks

Pharmaceutical Preparations Industry

374th out of 494 stocks


LMDX stock logo

About LumiraDx (NASDAQ:LMDX) Stock

LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has approximately 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions from the lab to point of need. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company was founded in 2014 and is headquartered in London, the United Kingdom.

Receive LMDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LumiraDx and its competitors with MarketBeat's FREE daily newsletter.

LMDX Stock News Headlines

LumiraDx (NASDAQ:LMDX) Price Target Cut to $1.00
LumiraDx (NASDAQ:LMDX) Rating Reiterated by 500.com
15 A.I. Trading Opportunities a Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
The Latest Analyst Ratings for LumiraDx
15 A.I. Trading Opportunities a Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
LumiraDx: Q1 Earnings Insights
LumiraDx Reports First Quarter 2023 Results
Earnings Preview For LumiraDx
LumiraDx Limited (NASDAQ:LMDX) Short Interest Update
See More Headlines
Receive LMDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LumiraDx and its competitors with MarketBeat's FREE daily newsletter.

LMDX Company Calendar

Last Earnings
3/21/2023
Today
5/29/2023
Next Earnings (Estimated)
8/17/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LMDX
Fax
N/A
Employees
1,210
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.14
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$0.85
Forecasted Upside/Downside
+346.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-447,790,000.00
Net Margins
-291.10%
Pretax Margin
-288.53%

Debt

Sales & Book Value

Annual Sales
$254.48 million
Book Value
($0.48) per share

Miscellaneous

Free Float
205,749,000
Market Cap
$152.59 million
Optionable
Not Optionable
Beta
0.96

Key Executives

  • Mr. Ron Zwanziger (Age 69)
    Co-Founder, Chairman & CEO
  • Dr. David Scott Ph.D. (Age 66)
    Co-Founder, CTO & Director
  • Dr. Jerome F. McAleer Ph.D. (Age 67)
    Co-Founder, Chief Scientist & Director
  • Mr. Dorian LeBlanc CPA (Age 47)
    CFO & VP of Global Operations
  • Ms. Veronique Ameye (Age 46)
    Exec. VP & Gen. Counsel
  • Ms. Colleen McMillen
    VP of Communications
  • Andy Ward
    National Sales Director - UK
  • Mr. Peter Scheu (Age 58)
    Pres of North American Commercial Operations
  • Mr. David Walton DMS (Age 69)
    Chief Commercial Officer
  • Dr. Nigel Lindner (Age 66)
    Chief Innovation Officer













LMDX Stock - Frequently Asked Questions

Should I buy or sell LumiraDx stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for LumiraDx in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LMDX shares.
View LMDX analyst ratings
or view top-rated stocks.

What is LumiraDx's stock price forecast for 2023?

3 analysts have issued 1 year target prices for LumiraDx's shares. Their LMDX share price forecasts range from $0.85 to $4.00. On average, they predict the company's stock price to reach $2.14 in the next twelve months. This suggests a possible upside of 346.2% from the stock's current price.
View analysts price targets for LMDX
or view top-rated stocks among Wall Street analysts.

How have LMDX shares performed in 2023?

LumiraDx's stock was trading at $0.90 at the beginning of 2023. Since then, LMDX shares have decreased by 46.8% and is now trading at $0.4790.
View the best growth stocks for 2023 here
.

When is LumiraDx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 17th 2023.
View our LMDX earnings forecast
.

How were LumiraDx's earnings last quarter?

LumiraDx Limited (NASDAQ:LMDX) announced its quarterly earnings results on Tuesday, March, 21st. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.13. The company earned $41.12 million during the quarter, compared to analyst estimates of $38.41 million. LumiraDx had a negative net margin of 291.10% and a negative trailing twelve-month return on equity of 2,145.42%.

What is LumiraDx's stock symbol?

LumiraDx trades on the NASDAQ under the ticker symbol "LMDX."

Who are LumiraDx's major shareholders?

LumiraDx's stock is owned by many different institutional and retail investors. Top institutional shareholders include Balyasny Asset Management L.P. (0.48%), Beacon Investment Advisory Services Inc. (0.17%) and Sound View Wealth Advisors Group LLC (0.02%).

How do I buy shares of LumiraDx?

Shares of LMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is LumiraDx's stock price today?

One share of LMDX stock can currently be purchased for approximately $0.48.

How much money does LumiraDx make?

LumiraDx (NASDAQ:LMDX) has a market capitalization of $152.59 million and generates $254.48 million in revenue each year. The company earns $-447,790,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis.

How many employees does LumiraDx have?

The company employs 1,210 workers across the globe.

How can I contact LumiraDx?

LumiraDx's mailing address is 99 SUMMER STREET SUITE 200, BOSTON MA, 02110. The official website for the company is www.lumiradx.com. The company can be reached via phone at 354-640-0540 or via email at ir@lumiradx.com.

This page (NASDAQ:LMDX) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -